Abstracts

INTRINSIC RESISTANCE OF RESERVOIR CELLS TO IMMUNE KILLING

Cytotoxic T-cell (CTL) responses against HIV play a critical role in partially controlling viral replication in the absence of antiretroviral therapy (ART) but fail to eradicate HIV reservoirs. The ability of these reservoirs to persist on ART, despite CTL, is generally attributed to 3 primary factors: i) viral latency – a barrier to detection by…

HOW TO GENERATE GOOD KILLERS BY INITIATING ART (NOT TOO) EARLY?

HIV infection results in significant defects in immune cell functions, including the inability to kill HIV infected cells due to chronic antigen exposure and immunosuppressive mechanisms triggered by chronic infection and inflammation. These immune dysfunctions are incompletely resolved by ART, resulting in viral reservoir persistence that impedes efforts to achieve long-term HIV remission. Two main…

BREAKING THE B-CELL FOLLICLE BARRIER TO ELIMINATE VIRAL RESERVOIRS

Follicular helper T cells (TFH) are a specialized subset of CD4+ T cells that interact with antigen-specific B cells within specialized structures known as germinal centers in B-cell follicles of secondary lymphoid tissues. This interaction is required for antibody affinity maturation and the differentiation of germinal center B cells into long-lived memory B cells and…

TYPE I INTERFERON RESISTANCE OF REBOUND HIV-1

Type 1 interferons (IFN-I) are potent innate antiviral effectors. However, harnessing these cytokines for HIV-1 prevention, treatment, and cure strategies has been hampered by an incomplete understanding of the role of endogenously produced IFN-I in viral control. To examine the kinetics of the IFN-I response over the course of HIV-1 infection, we generated 500 clonally-derived…

TRIPLE DRUG ART, DUAL ART, OR JUST ART?

Over the last 2 years, for the first time in the history of modern antiretroviral therapy (ART), expert guidelines (EACS, DHHS, IAS–USA) have started to include two-drug ART regimens as recommended combinations for most people with HIV (PWH), both as initial and as maintenance therapy in the setting of virological suppression. Currently 2-drug ART can…

NOVEL ANTIRETROVIRAL THERAPIES IN CLINICAL DEVELOPMENT

Innovative drugs in the development pipeline for HIV treatment are at a crossroads. The model of introducing drugs with incremental improvements within existing drug classes is now fading. Drugs aimed at novel targets may have a greater impact, especially for providing new options in individuals multi-exposed to ARVs. The scientific community has moved research into…

ARVs AND ART FOR NEWBORNS AND INFANTS: A LAST FRONTIER

This state-of-the-ART talk on antiretroviral drugs and antiretroviral treatment in neonates and infants will focus on: • The considerations when evaluating the safety and dosing of new ARVs in infants and young children • The additional considerations when treating premature infants with antiretroviral drugs for prophylaxis or treatment • The evolving paradigm around the use…